Nick Latimer joins Delta Hat

We are excited to share that Professor Nick Latimer will be joining the Delta Hat team from January. Nick is a Professor of Health Economics at the University of Sheffield, and will join on a part time basis. Nick’s research focuses on survival analysis in economic evaluations, and he’s authored four NICE Decision Support Unit technical support documents related to survival analysis, treatment switching, and partitioned survival models. He has been a member of NICE Technology Appraisal Committee B for 5 years. Nick will be helping out on projects and will also be doing some of the analyses himself.

We are excited to share that Professor Nick Latimer will be joining the Delta Hat team from January. Nick is a Professor of Health Economics at the University of Sheffield, and will join on a part time basis. Nick’s research focuses on survival analysis in economic evaluations, and he’s authored four NICE Decision Support Unit technical support documents related to survival analysis1,2, treatment switching3, and partitioned survival models4. He has been a member of NICE Technology Appraisal Committee B for 5 years. Nick will be helping out on projects and will also be doing some of the analyses himself.

In the past, Nick’s research has focused on methods for adjusting survival estimates in the presence of treatment switching in clinical trials5–9. He did doctoral and post-doctoral fellowships on this topic. This involved learning a lot about causal inference methods, and more recently Nick’s focus has been on investigating the use of these methods to analyse cancer registry datasets, to estimate the comparative effectiveness of cancer treatments used in clinical practice10–12.

Nick teaches on several MSc courses at the University of Sheffield, and also regularly teaches short courses on survival analysis, treatment switching, and causal inference. He currently supervises 3 PhD students who are investigating survival analysis and causal inference methods. He has published over 70 articles in peer-reviewed journals.

In his spare time Nick likes to ride his bike, especially up hills.

1. Latimer, N. (2011). NICE DSU technical support document 14: Survival analysis for economic evaluations alongside clinical trials-extrapolation with patient-level data. National Institute for Health and Care Excellence (NICE).
2. Rutherford, M. J., Lambert, P. C., Sweeting, M. J., Pennington, B., Crowther, M. J., Abrams, K. R., & Latimer, N. R. (2019). NICE DSU Technical Support Document 21: Flexible Methods for Survival Analysis. National Institute for Health and Care Excellence (NICE).
3. Latimer, N. R., & Abrams, K. R. (2014). NICE DSU technical support document 16: Adjusting survival time estimates in the presence of treatment switching. National Institute for Health and Care Excellence (NICE).
4. Woods, B., Sideris, E., Palmer, S., Latimer, N., & Soares, M. (2017). NICE DSU Technical Support Document 19: Partitioned Survival Analysis for Decision Modelling in Health Care: A Critical Review. National Institute for Health and Care Excellence (NICE).
5. Latimer, N. R. (2013). Survival analysis for economic evaluations alongside clinical trialsextrapolation with patient-level data: Inconsistencies, limitations, and a practical guide. Medical Decision Making, 33(6).
6. Latimer, N. R., Abrams, K. R., Lambert, P. C., Crowther, M. J., Wailoo, A. J., Morden, J. P., Akehurst, R. L., & Campbell, M. J. (2014). Adjusting survival time estimates to account for treatment switching in randomized controlled trialsan economic evaluation context: Methods, limitations, and recommendations. Medical Decision Making, 34(3), 387402.
7. Latimer, N. R., Abrams, K., Lambert, P., Crowther, M., Wailoo, A., Morden, J., Akehurst, R., & Campbell, M. (2017). Adjusting for treatment switching in randomised controlled trialsa simulation study and a simplified two-stage method. Statistical Methods in Medical Research, 26(2), 724751.
8. Latimer, N. R., Henshall, C., Siebert, U., & Bell, H. (2016). Treatment switching: Statistical and decision-making challenges and approaches. International Journal of Technology Assessment in Health Care, 32(3), 160166.
9. Latimer, N. R., Amonkar, M. M., Stapelkamp, C., & Sun, P. (2015). Adjusting for confounding effects of treatment switching in a randomized phase II study of dabrafenib plus trametinib in BRAF V600+ metastatic melanoma. Melanoma Research, 25(6), 528536.
10. Latimer, N. R., & Adler, A. I. (2022). Extrapolation beyond the end of trials to estimate long term survival and cost effectiveness. BMJ Medicine, 1(1).
11. Gray, J., Sullivan, T., Latimer, N. R., Salter, A., Sorich, M. J., Ward, R. L., & Karnon, J. (2021). Extrapolation of survival curves using standard parametric models and flexible parametric spline models: Comparisons in large registry cohorts with advanced cancer. Medical Decision Making, 41(2), 179193.
12. Jackson, C., Stevens, J., Ren, S., Latimer, N., Bojke, L., Manca, A., & Sharples, L. (2017). Extrapolating survival from randomized trials using external data: A review of methods. Medical Decision Making, 37(4), 377390.

References